iShares MSCI World ETF: A Fee Premium and a Forced Reshuffle

iShares MSCI World ETF's 19% YTD return faces tech earnings tests, healthcare tariffs, and a looming 2026 index overhaul amid intense fee competition.

The $8 billion iShares MSCI World ETF (URTH) is navigating a critical period defined by corporate earnings, geopolitical headwinds, and a looming structural overhaul. While the fund’s 19% year-to-date return reflects robust market performance, its future trajectory hinges on a packed calendar of company results and a historic index change scheduled for May 2026.

This week, the spotlight falls squarely on the technology sector, which commands nearly 27% of the ETF’s portfolio. Microsoft, accounting for a significant portion of that weight, reports earnings on April 29. Its shares currently trade more than 30% below their all-time high, with investor concern focused on its massive cloud contract backlog despite Azure's recent rapid growth. TD Cowen maintains a buy rating but trimmed its price target to $540, citing tight GPU capacity. Analysts expect the company to post adjusted earnings per share of $16.46 for the fiscal year, a 21% year-over-year increase.

Apple follows on April 30, arriving with notable momentum. The company recently surprised markets with a 20% jump in iPhone shipments to China, defying a 4% contraction in the broader Chinese smartphone market. Together, these two tech giants comprise roughly 8% of the URTH’s holdings, a substantial concentration for a fund with about 1,300 positions across 23 developed markets.

Providing a counterbalance to tech’s uncertainty, the financial sector—the fund’s second-largest industry allocation—has already delivered strong first-quarter results. Morgan Stanley saw net income surge 29% to $5.57 billion, while JPMorgan Chase recorded record trading revenue of $11.6 billion, beating profit estimates by approximately 9%. This strength supports the broader FactSet forecast for S&P 500 earnings growth of 12.5% in Q1 2026, which would mark the longest such growth streak in over a decade.

However, not all sectors are contributing positively. The healthcare segment, representing 9.45% of the URTH, faces a new challenge. US tariffs of up to 15% on imported pharmaceutical products from Europe and Asia are set to take effect in late July. Analysts warn this could trigger an inflation spike of around 0.5 percentage points and compress margins for affected companies, leading FactSet to already lower profit forecasts for the industry.

Simultaneously, the ETF provider landscape is witnessing intense fee competition. Rivals like Invesco and UBS have slashed management fees on their MSCI World ETFs to minimal levels of 0.05% and 0.06%, respectively, with BNP Paribas already at that lowest tier since September 2025. BlackRock defends the iShares product’s higher 0.24% fee by pointing to its extremely low tracking difference of just 0.02% and high liquidity. This argument appears to hold weight with major investors; the Royal Bank of Canada increased its position by 17.5% to roughly two million shares in Q4 2025.

Looking ahead, a monumental index reconstitution looms. In May 2026, MSCI will implement a fundamental change to its free-float calculation methodology, introducing a new three-tier classification system. This reform is expected to force massive portfolio shifts within the URTH, far exceeding typical quarterly rebalances and potentially altering the weights of mega-caps like Nvidia significantly.

Further potential volatility stems from a landmark IPO. SpaceX is targeting a June listing on the Nasdaq with an estimated valuation exceeding $1 trillion, an event that would further skew the MSCI World’s US weighting.

Investors can expect a dividend payout from the fund on June 15. The ETF has recently seen dividend growth surpass 20%. Yet, the confluence of earnings reports, trade policy, and the impending index revolution ensures the URTH’s path remains one to watch closely.